Productivity enhancing bioreactor for scalable organoid culture

AMSBIO (Oxford, UK) has announced RPMotion, a spinning organoid bioreactor that facilitates fast, easy and efficient organoid culture for drug discovery, disease modeling and regenerative medicine. 

Until now, organoid expansion has been an expensive and time-consuming static process, requiring large amounts of materials, skilled labour and time. Benefiting from a novel bioreactor design, the RPMotion overcomes current limitations in organoid expansion/differentiation methodologies, helping laboratories improve efficiency and reduce reliance on manual processes. 

Design optimized for automated small-scale (5-50ml) expansion and differentiation of organoids – the easy-to-use RPMotion delivers on average 5-fold faster organoid expansion compared to current culture methods. As a result, labs using the RPMotion can expect to reduce the cost of organoid culture ingredients by 60%, and labour use by 75%. This unique organoid bioreactor needs minimal attention and can be monitored without even opening the incubator. 

The compact RPMotion is controlled through an intuitive external LCD screen, which allows the user to cycle through different programs that fit the needs of their specific organoid type. To further increase productivity, the RPMotion has a multiplex feature, allowing it to run four tubes in parallel, thereby enabling simultaneous experiments, and up to 28 additional bioreactors can be connected through a simple plug-and-play feature controlled by one LCD screen. 

Not only does the RPMotion improve organoid culture productivity, but this bioreactor is also ideal to aid in the production of consistent, high-quality organoids, making it ideal for GMP-aligned workflows.  

For further information: the RPMotion spinning organoid bioreactor

About AMSBIO

AMSBIO, part of the Europa Biosite group, is a leading life sciences company supporting drug discovery, translational research and cell and gene therapy across Europe, North America and wider international markets. With in-depth expertise in advanced cell culture, 3D cell models and cryopreservation, AMSBIO is well placed to help researchers progress from early discovery through to clinical and GMP-ready applications. The company’s portfolio of innovative products and services supports multiple stages of the research pipeline, spanning target discovery, assay development and disease modeling, through to stem cell and organoid-based research. Key solutions include the integrated stem cell platform combining StemFit™ media, iMatrix™ recombinant laminins and CELLBANKER™ cryopreservation technology, alongside extracellular matrix technologies, biospecimens, glycobiology tools, kits and assays, and a wide range of custom services, including viral delivery. Drawing on extensive GMP expertise and a comprehensive human and animal biorepository, AMSBIO is internationally recognized for delivering high-quality, application-ready products and services. AMSBIO has a consistent record of close scientific collaboration with partners in academic, biotech and pharmaceutical markets to translate innovation from bench to bedside.